Xintela AB
- Biotech or pharma, therapeutic R&D
Xintela's Best-in-Class stem cell product XSTEM® is in clinical development (Phase I/IIa) in knee osteoarthritis (OA) and difficult-to-heal venous leg ulcers (VLU). An interim analysis of the OA study has demonstrated safety and positive efficacy results, 18-month after XSTEM treatment. The results support a disease modifying potential of XSTEM. Upcoming final study report will show up to 24-month data. The VLU study is also near completion.
Xintela's wholly-owned subsidiary Targinta, has developed selective First-in Class antibodies TARG9 (ADC) and TARG10 (function blocking ) targeting the novel cancer target integrin alpha10beta1. Preclinical studies have demonstrated strong inhibition of tumor growth and metastasis in animal models for solid aggressive cancers including glioblastoma and triple-negative breast cancer.
Xintela is interested in meeting with potential partners and investors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}